Live webcast fireside chat on Thursday, December 4th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced JD Finley, Chief Executive Officer and Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, will participate in a fireside chat at the Piper San ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR WASHINGTON, D.C. 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33672 PALISADE BIO, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporati ...

A downtrend has been apparent in Palisade Bio, Inc. (PALI) lately. While the stock has lost 18.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ...

Core Viewpoint - Palisade Bio, Inc. (PALI) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Ratings - The Zacks rating system is based solely on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Palisade Bio reflects an improvement in the company's earnings outlook, which is expected to lead to increased buying pressure and a rise in stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in a company's future earnings potential, as shown through earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to significant stock price movements based on their buying or selling activities [5]. Performance of Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The system maintains a balanced distribution of "buy" and "sell" ratings across over 4,000 stocks, ensuring that only the top 20% receive a "Strong Buy" or "Buy" rating [10][11]. Specifics on Palisade Bio - For the fiscal year ending December 2025, Palisade Bio is expected to earn -$1.33 per share, unchanged from the previous year, but analysts have raised their estimates by 4.7% over the past three months [9].

Core Insights - Palisade Bio has appointed Sharon Skare, PhD(c), as Vice President, Global Head of Clinical Operations, bringing over 24 years of experience in clinical development across various therapeutic areas [1][3][4] - The company is focused on advancing PALI-2108 for ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 IND submission planned for the first half of 2026 [1][7] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases [8] - The company aims to transform the treatment landscape by utilizing a targeted approach with its novel therapeutics [8] Product Development - PALI-2108 is an orally administered prodrug designed for local delivery of phosphodiesterase-4 (PDE4) inhibition specifically to the terminal ileum and colon [5] - The prodrug is engineered to be gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes [5][6] - A Phase 1a/1b study of PALI-2108 for ulcerative colitis has been completed with positive data, and a Phase 1b study for fibrostenotic Crohn's disease is currently underway [7] Leadership and Expertise - Sharon Skare has a strong background in global clinical development, having previously held senior positions at Abivax, Pfizer, and Arena Pharmaceuticals [3][4] - Her experience includes overseeing global Phase 3 and Phase 2 programs in ulcerative colitis and Crohn's disease, as well as leading clinical operations for Etrasimod, now approved as Velsipity™ [3][4]

Core Viewpoint - Purcell & Lefkowitz LLP is investigating Palisade Bio, Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is being conducted on behalf of Palisade Bio's shareholders [1]. - Shareholders interested in more information about their rights and options can contact Purcell & Lefkowitz LLP [2]. - The law firm specializes in representing shareholders affected by securities fraud and breaches of fiduciary duty [3].

Core Insights - Palisade Bio has initiated a Phase 1b clinical study for PALI-2108, a first-in-class PDE4 inhibitor prodrug targeting fibrostenotic Crohn's disease (FSCD), with topline data expected in Q1 2026 [2][3][5] Group 1: Clinical Development - The Phase 1b study will enroll approximately 6 to 12 patients and aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PALI-2108 over a 14-day treatment period [3][4] - PALI-2108 is designed for targeted activation in the terminal ileum and colon, providing high local tissue exposure with minimal systemic absorption [3][6] - The study will also assess tissue-level pharmacology and molecular responses using paired ileal biopsies and peripheral blood mononuclear cells (PBMCs) [4] Group 2: Future Plans - Data from the Phase 1b study, along with results from the Phase 1a/1b ulcerative colitis program, are expected to support Phase 2 Investigational New Drug (IND) submissions to the FDA in the first half of 2026 [5] - The company aims to transform the treatment landscape for autoimmune, inflammatory, and fibrotic diseases through its targeted therapeutic approach [7]

Core Insights - Palisade Bio has developed PALI-2108, a first-in-class PDE4 inhibitor specifically targeting the terminal ileum and colon for treating fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to meet significant unmet medical needs [1][4] Intellectual Property - The Canadian Intellectual Property Office has granted patent number 3,174,137 for PALI-2108, providing composition-of-matter protection until May 28, 2041 [2] - The patent covers the unique design of PALI-2108, which includes a galactose-derived sugar moiety that minimizes absorption until activated by colonic bacteria [2] Clinical Development - Palisade Bio is advancing PALI-2108 in a Phase 1b study for FSCD, with patient dosing expected to start in the second half of 2025 and topline data anticipated in the first quarter of 2026 [3] - Results from the Phase 1b study, along with data from completed Phase 1a/1b trials in UC, will support a planned Phase 2 IND submission to the FDA in the first half of 2026 [3] Product Overview - PALI-2108 is an orally administered prodrug designed for gut-restricted delivery, achieving high local tissue concentrations while minimizing systemic exposure [4] - The mechanism of action aims to maximize anti-inflammatory and anti-fibrotic effects while reducing common tolerability issues associated with systemic PDE4 inhibitors [4] Company Background - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [5]

Key Points - Several biotech stocks experienced notable after-hours gains on October 9, driven by new data and corporate developments [1] Company Summaries Palisade Bio Inc. (PALI) - Shares traded at $2.26 in after-hours, reflecting a 7.62% gain from the prior close of $2.10, which was up 5% on the day [1] - The company cancelled its special meeting of stockholders due to lack of quorum, withdrawing all proposals from consideration [2] Healthcare Triangle Inc. (HCTI) - Shares traded at $2.88 in after-hours, up 4.35% from the regular session close of $2.76, which was down 17.86% [3] - The company signed a non-binding Letter of Intent to acquire Teyame.AI, projected to generate $34 million in revenue for fiscal year 2025 [4] Nutriband Inc. (NTRB) - Shares traded at $8.25 in after-hours, up 4.30% from the regular session close of $7.91, which was down 6.94% [5] - The company filed a provisional patent application with the USPTO to strengthen its intellectual property for its AVERSA abuse deterrent transdermal [5] Karyopharm Therapeutics Inc. (KPTI) - Shares traded at $6.08 in after-hours, up 4.46% from the regular session close of $5.82, which had declined 1.36% [6] - The company announced financing transactions expected to provide $100 million in financial flexibility, extending its cash runway into Q2 2026 [6] Editas Medicine Inc. (EDIT) - Shares traded at $4.22 in after-hours, up 3.43% from the regular session close of $4.08, which was down 1.69% [7] - The company presented new preclinical proof-of-concept data for its therapy EDIT-401, showing a 90% LDL-C reduction in non-human primates and mice [7] CG Oncology Inc. (CGON) - Shares traded at $45.40 in after-hours, up 2.11% from the regular session close of $44.46, which gained 9.21% [8] - No official news releases or filings were issued during the day [8]

Core Viewpoint - Palisade Bio, Inc. has decided to cancel its special meeting of stockholders originally scheduled for October 10, 2025, due to the lack of a required quorum [1][2]. Group 1: Special Meeting Details - The special meeting was previously adjourned to September 26, 2025, but was adjourned again without any business being conducted due to insufficient proxies to form a quorum [2]. - The company has not received the necessary proxies to constitute a quorum and has withdrawn the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025 [2]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [3]. - The company aims to transform the treatment landscape through a targeted approach with its novel therapeutics [3].